Resources
Case Study
Case Study: A Strategy to Eliminate Hemostatic Risk in Plasma-Derived Biotherapeutic Formulation
Human blood plasma is rich in proteins, including immunoglobulins (IgG), coagulationfactors (Factors II, VIII, IX, and X), alpha-1 antitrypsin, fibrin sealants, and albumin.These proteins boost the immune system and fight inflammation and infection, makingplasma-derived biotherapeutics useful in treating rare, chronic, and often geneticdiseases. Unfortunately, the current worldwide demand for intravenous IgG (IVIG)products exceeds current plasma
De-Risking a Biotherapeutic Product With HRMS HCP Analysis
Learn more in our case study on how we used our advanced HRMS capabilities, detailed analytical outputs, and close, transparent communication to quickly identify high-risk proteins and advise process changes to de-risk a client’s biotherapeutic. Read the Case Study Now:
De-Risking a Biotherapeutic Product With HRMS HCP Analysis Read More »
Development of a Novel Plasma Fractionation Process for the Production of Immune Globulin
A highly efficient method of plasma fractionation that has the potential to address the growing global IG product shortage. Read the Case Study Now:
Problematic Host Cell Proteins – Clusterin
When doing Host Cell Protein analysis by mass spectrometry, we often fail to appreciate the “why” of the HCPs that show up in our protein lists – why did these HCPs co-purify with the Product, and why are they important? Clusterin shows up in almost every HCP project we work on. Why?